Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical Products Administration (NMPA) has accepted for review a clinical trial filing for JS125 (WJ47156), a histone deacetylases (HDAC) inhibitor co-developed with Wigen Biomedicine Technology (Shanghai) Co., Ltd. This epigenetic regulator is intended for the treatment of malignant tumors.
HDACs play a crucial role in the regulation of acetylation and deacetylation of lysine residues in histones and non-histones, and their activity is closely associated with the development of various types of malignant tumors. JS125 is designed to selectively inhibit HDAC1, HDAC2, and HDAC3, thereby exhibiting anti-tumor effects. It works by inducing cell cycle arrest, inhibiting angiogenesis, modulating immune responses, and promoting cancer cell senescence and apoptosis, all of which contribute to the treatment of tumors.- Flcube.com
